Cloughesy, 2019
pembrolizumab plus SoC (n=16) vs. Standard of Care (SoC) (n=19)
randomized controlled trial
pembrolizumab plus chemotherapy
pembrolizumab as neoadjuvant
chemotherapy
all patients received adjuvant chemotherapy
glioblastoma (GB)
open label
PILOT STUDY : objectives did not estimate clinical benefits